153 related articles for article (PubMed ID: 38195889)
1. Med23 deficiency reprograms the tumor microenvironment to promote lung tumorigenesis.
Fu X; Liu S; Cao D; Li C; Ji H; Wang G
Br J Cancer; 2024 Mar; 130(5):716-727. PubMed ID: 38195889
[TBL] [Abstract][Full Text] [Related]
2. Mig-6 deficiency cooperates with oncogenic Kras to promote mouse lung tumorigenesis.
Liu J; Cho SN; Wu SP; Jin N; Moghaddam SJ; Gilbert JL; Wistuba I; DeMayo FJ
Lung Cancer; 2017 Oct; 112():47-56. PubMed ID: 29191600
[TBL] [Abstract][Full Text] [Related]
3. Selective requirement for Mediator MED23 in Ras-active lung cancer.
Yang X; Zhao M; Xia M; Liu Y; Yan J; Ji H; Wang G
Proc Natl Acad Sci U S A; 2012 Oct; 109(41):E2813-22. PubMed ID: 22988093
[TBL] [Abstract][Full Text] [Related]
4. Senescent Macrophages Promote KRAS-Driven Lung Tumorigenesis.
Cancer Discov; 2023 Aug; 13(8):1758. PubMed ID: 37326376
[TBL] [Abstract][Full Text] [Related]
5. T-cells null for the MED23 subunit of mediator express decreased levels of KLF2 and inefficiently populate the peripheral lymphoid organs.
Kasper LH; Fukuyama T; Brindle PK
PLoS One; 2014; 9(7):e102076. PubMed ID: 25054639
[TBL] [Abstract][Full Text] [Related]
6. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
[TBL] [Abstract][Full Text] [Related]
7. Mediator subunit 23 overexpression as a novel target for suppressing proliferation and tumorigenesis in hepatocellular carcinoma.
Guo Y; Wang J; Li H; Liu W; Chen D; Zhao K; Liang X; Zhang Q; Yang Y; Chen G
J Gastroenterol Hepatol; 2015 Jun; 30(6):1094-103. PubMed ID: 25684393
[TBL] [Abstract][Full Text] [Related]
8. Mediator MED23 regulates basal transcription in vivo via an interaction with P-TEFb.
Wang W; Yao X; Huang Y; Hu X; Liu R; Hou D; Chen R; Wang G
Transcription; 2013; 4(1):39-51. PubMed ID: 23340209
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of mediator MED23 in non-small-cell lung cancer promotes the growth, migration, and metastasis of cancer cells.
Shi J; Liu H; Yao F; Zhong C; Zhao H
Tumour Biol; 2014 Dec; 35(12):12005-13. PubMed ID: 25273169
[TBL] [Abstract][Full Text] [Related]
10. The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.
Lee JW; Zhang Y; Eoh KJ; Sharma R; Sanmamed MF; Wu J; Choi J; Park HS; Iwasaki A; Kaftan E; Chen L; Papadimitrakopoulou V; Herbst RS; Koo JS
J Thorac Oncol; 2019 Jun; 14(6):1046-1060. PubMed ID: 30771521
[TBL] [Abstract][Full Text] [Related]
11. Circadian disruption enhances HSF1 signaling and tumorigenesis in
Pariollaud M; Ibrahim LH; Irizarry E; Mello RM; Chan AB; Altman BJ; Shaw RJ; Bollong MJ; Wiseman RL; Lamia KA
Sci Adv; 2022 Sep; 8(39):eabo1123. PubMed ID: 36170373
[TBL] [Abstract][Full Text] [Related]
12. Med23 supports angiogenesis and maintains vascular integrity through negative regulation of angiopoietin2 expression.
Yang Y; Xiao Q; Yin J; Li C; Yu D; He Y; Yang Z; Wang G
Commun Biol; 2022 Apr; 5(1):374. PubMed ID: 35440711
[TBL] [Abstract][Full Text] [Related]
13. Mediator Med23 Regulates Adult Hippocampal Neurogenesis.
Chen GY; Zhang S; Li CH; Qi CC; Wang YZ; Chen JY; Wang G; Ding YQ; Su CJ
Front Cell Dev Biol; 2020; 8():699. PubMed ID: 32850819
[TBL] [Abstract][Full Text] [Related]
14. Mediator MED23 cooperates with RUNX2 to drive osteoblast differentiation and bone development.
Liu Z; Yao X; Yan G; Xu Y; Yan J; Zou W; Wang G
Nat Commun; 2016 Apr; 7():11149. PubMed ID: 27033977
[TBL] [Abstract][Full Text] [Related]
15. Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer.
Tan X; Carretero J; Chen Z; Zhang J; Wang Y; Chen J; Li X; Ye H; Tang C; Cheng X; Hou N; Yang X; Wong KK
PLoS One; 2013; 8(11):e80885. PubMed ID: 24260500
[TBL] [Abstract][Full Text] [Related]
16. Kras
Cheng H; Fan K; Luo G; Fan Z; Yang C; Huang Q; Jin K; Xu J; Yu X; Liu C
Cancer Lett; 2019 Apr; 446():103-111. PubMed ID: 30664964
[TBL] [Abstract][Full Text] [Related]
17. The Tian-Men-Dong decoction suppresses the tumour-infiltrating G-MDSCs via IL-1β-mediated signalling in lung cancer.
Su L; Zhang F; Liu MX; Li H; Li Q; Zhu YZ; Hou YF; Chen X; Wang XY; Qian CM; Yao C; Wang LX; Jiao XN; Zhu XD; Xu ZH; Zou CP
J Ethnopharmacol; 2023 Sep; 313():116491. PubMed ID: 37072091
[TBL] [Abstract][Full Text] [Related]
18. E3 ligase TRIM28 promotes anti-PD-1 resistance in non-small cell lung cancer by enhancing the recruitment of myeloid-derived suppressor cells.
Liang M; Sun Z; Chen X; Wang L; Wang H; Qin L; Zhao W; Geng B
J Exp Clin Cancer Res; 2023 Oct; 42(1):275. PubMed ID: 37865804
[TBL] [Abstract][Full Text] [Related]
19. Opposing role of Notch1 and Notch2 in a Kras(G12D)-driven murine non-small cell lung cancer model.
Baumgart A; Mazur PK; Anton M; Rudelius M; Schwamborn K; Feuchtinger A; Behnke K; Walch A; Braren R; Peschel C; Duyster J; Siveke JT; Dechow T
Oncogene; 2015 Jan; 34(5):578-88. PubMed ID: 24509876
[TBL] [Abstract][Full Text] [Related]
20. NOS2 enhances KRAS-induced lung carcinogenesis, inflammation and microRNA-21 expression.
Okayama H; Saito M; Oue N; Weiss JM; Stauffer J; Takenoshita S; Wiltrout RH; Hussain SP; Harris CC
Int J Cancer; 2013 Jan; 132(1):9-18. PubMed ID: 22618808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
